Clinical study evaluating MP-0712
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs MP 0712 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- 03 Feb 2025 New trial record
- 12 Jan 2025 According to Molecular Partners media release, company to advance 212Pb-Radio-DARPin, DLL3-targeted MP0712 into clinical trials in 2025.
- 31 Oct 2024 According to Molecular Partners media release, Initial clinical data of MP0712 is also anticipated in 2025.